Biotech breakthrough
Every scenario in which biotech breakthrough is a modeled driver — one risk, read across the whole library.
92 scenarios touch this risk, ranked by probability.
58%▼ 1–3 years
What if IRA Part D negotiation round-2 caps 15 more blockbuster prices?
44%▲ 3–10 years
What if GLP-1s reshape food, beverage and dialysis demand for a decade?
41%▲ 3–10 years
What if Multi-cancer early-detection blood tests reach Medicare coverage?
41%▲ 3–10 years
What if Pharma's age-related-disease pipeline rides the aging dividend?
38%▲ 3–10 years
What if CRISPR cures common diseases?
38%▲ 3–10 years
What if Whole-genome screening at birth?
38%▼ 1–3 years
What if Keytruda 2028 patent cliff erases $25B Merck revenue base?
38%▼ 1–3 years
What if $300B loss-of-exclusivity wave hits big pharma through 2030?
38%▼ 1–3 years
What if Bristol-Myers Eliquis/Opdivo cliff guts cardiovascular cash flow?
38%▼ 1–3 years
What if J&J Stelara biosimilar erosion accelerates faster than guidance?
38%▼ 1–3 years
What if IRA expands price negotiation to Part B physician-administered drugs?
38%▲ 3–10 years
What if Pharma pipeline renaissance: post-cliff growth resumes by 2030?
38%▲ 3–10 years
What if Biomarker-guided launches reshape pharma R&D and launch economics?
38%▲ 3–10 years
What if GLP-1 and anti-aging therapies extend healthspan, lift longevity bets?
37%▲ 1–3 years
What if GLP-1 pills go mass-market?
37%▲ 3–10 years
What if Malaria and HIV vaccines deploy?
37%▲ 3–10 years
What if Brain interface restores function?
37%▲ 1–3 years
What if GLP-1 obesity market crosses $100B as Lilly-Novo duopoly compounds?
37%▲ 1–3 years
What if Lilly Zepbound outsells Novo Wegovy as US supply normalizes?
37%▲ 1–3 years
What if GLP-1 cardiovascular and kidney label expansions unlock payer coverage?
37%▲ 1–3 years
What if Oral obesity-pill price war expands access to 50M+ patients?
37%▲ 1–3 years
What if Big-pharma M&A wave deploys $500B to fill the patent cliff?
37%▲ 1–3 years
What if ADC boom rewires oncology and lifts AstraZeneca/Daiichi Sankyo?
37%▲ 1–3 years
What if Surgical-robotics super-cycle lifts Intuitive as competitors enter?
37%▲ 3–10 years
What if AI-designed drugs cut discovery timelines and lift platform biotechs?
36%▲ 1–3 years
What if AI halves drug-discovery time?
36%▲ 1–3 years
What if IRA 'pill penalty' fix spurs small-molecule R&D rebound?
36%▲ 1–3 years
What if Bispecific and CAR-T pipeline pushes immuno-oncology past chemo era?
36%▲ 1–3 years
What if Robotic surgery and AI imaging drive a med-device capex upgrade cycle?
36%▲ 1–3 years
What if Alzheimer's anti-amyloid uptake scales after blood-test diagnosis?
36%▲ 3–10 years
What if Longevity/anti-aging clinical proof opens a new pharma growth frontier?
36%▲ 3–10 years
What if Wearables and digital-health diagnostics scale into mainstream care?
36%▲ 3–10 years
What if Anti-aging biotech breakthrough adds healthy years to the workforce?
35%▲ 1–3 years
What if FTC eases pharma-merger blockade, unleashing pent-up bid pipeline?
34%▲ 3–10 years
What if Universal cancer vaccine works?
34%▲ 1–3 years
What if Weight-loss-drug halo lifts the entire metabolic-disease pipeline?
34%▲ 3–10 years
What if Longevity breakthroughs spark a new biotech and healthspan bull?
33%▲ 3–10 years
What if AI diagnostics beat doctors?
33%▲ 1–3 years
What if Pharma tariff threat triggers $200B US manufacturing reshore pledges?
32%▲ 3–10 years
What if Alzheimer's is reversed?
32%▲ 1–3 years
What if China biotech licensing wave feeds Western pharma pipelines cheaply?
32%▲ 1–3 years
What if Life-science tools demand rebounds as biopharma R&D budgets thaw?
32%▼ 1–3 years
What if Biosimilar erosion validates a structural pharma-margin reset?
32%▲ 1–3 years
What if Obesity-drug supply expansion drives med-tech and CDMO capex orders?
31%▲ 3–10 years
What if Lab-grown organs end waitlists?
30%▲ 3–10 years
What if AI ends major bottleneck diseases?
29%▲ 1–3 years
What if AI designs superbug antibiotics?
29%▼ 1–3 years
What if MFN drug-pricing rule survives court challenge and takes effect?
29%▲ 1–3 years
What if Gene-therapy reimbursement breakthrough revives one-time-cure model?
29%▲ 1–3 years
What if Specialty-pharma rare-disease launches drive durable high-margin growth?
29%▲ 1–3 years
What if CRISPR in-vivo editing milestone re-rates the gene-editing cohort?
29%▲ 1–3 years
What if Mental-health and neuro pipeline (KarXT-style) opens a CNS growth wave?
29%▲ 1–3 years
What if Medtech electrification ties device makers to the power-capex theme?
29%▼ 1–3 years
What if Tariff/IRA double-hit forces pharma to cut R&D and de-rate further?
29%▲ 1–3 years
What if Radioligand-therapy boom lifts Novartis and isotope suppliers?
29%▲ 1–3 years
What if Immunology pipeline (oral IL-23/TL1A) sustains big-pharma growth engines?
29%▲ 1–3 years
What if Cardiometabolic outcomes data turns GLP-1s into standard preventive care?
29%▲ 1–3 years
What if China-pharma PD-1/ADC innovation reshapes oncology competition?
29%▲ 1–3 years
What if Obesity-care ecosystem (telehealth, devices) scales a new vertical?
29%▲ 1–3 years
What if mRNA-platform pipeline (oncology, RSV, combos) revives vaccine growth?
29%▲ 1–3 years
What if Biotech breadth thrust as clinical-data wins reopen risk appetite?
27%▲ 3–10 years
What if Cultivated food frees farmland?
27%▲ 1–3 years
What if Healthcare-equity re-rating on AI-accelerated drug pipelines?
27%▼ 1–3 years
What if Compounded-GLP-1 crackdown and biosimilars compress Novo pricing?
24%▲ 3–10 years
What if Longevity drug adds a decade?
24%▲ 3–10 years
What if Drought-resistant GMO crops stabilize global yields?
22%▼ 6–18 months
What if Most-Favored-Nation executive order ties US drug prices to OECD floor?
22%▼ 6–18 months
What if Section 232 pharma tariffs hit Irish/Swiss-made US drug imports?
22%▼ 6–18 months
What if API tariffs expose US generic-drug shortage fragility?
22%▲ 6–18 months
What if GLP-1 coverage mandate detonates health-insurer cost structure?
22%▼ 6–18 months
What if GLP-1 safety scare on muscle loss or NAION dents obesity-stock premium?
22%▼ 6–18 months
What if Mega-merger attempt collides with FTC and freezes deal sentiment?
22%▼ 6–18 months
What if Key ADC phase-3 miss deflates the oncology innovation premium?
22%▼ 6–18 months
What if Higher-for-longer rates trigger biotech cash-runway insolvency wave?
22%▼ 6–18 months
What if RFK-led HHS vaccine-policy shift dents vaccine-maker revenue?
22%▼ 6–18 months
What if FDA leadership turnover and staffing cuts slow drug approvals?
22%▼ 6–18 months
What if Drug-pricing populism spills into a broad pharma sentiment de-rating?
22%▼ 6–18 months
What if Generic-injectable shortages force emergency federal supply intervention?
22%▼ 6–18 months
What if Pharma litigation and opioid-style liabilities pressure sector sentiment?
21%▲ 6–18 months
What if Pharma 'voluntary' direct-to-patient pricing blunts MFN threat?
21%▲ 6–18 months
What if Lilly orforglipron oral GLP-1 phase-3 win opens mass obesity market?
21%▲ 6–18 months
What if Pfizer/Viking oral GLP-1 readout cracks the Lilly-Novo duopoly?
21%▲ 6–18 months
What if Rate cuts reopen biotech M&A and the XBI takeout premium?
21%▲ 6–18 months
What if Fed rate cuts re-rate long-duration biotech off multi-year lows?
21%▲ 6–18 months
What if Biotech IPO and follow-on window reopens after a two-year drought?
21%▼ 6–18 months
What if Novo Nordisk guidance cut signals GLP-1 growth deceleration?
21%▼ 6–18 months
What if BIOSECURE-style China decoupling disrupts CDMO supply chains?
21%▲ 1–3 years
What if Antimicrobial-resistance crisis revives antibiotic-developer economics?
21%▼ 6–18 months
What if Pharma earnings de-rating as cliff-year guidance disappoints?
21%▼ 6–18 months
What if Medicaid cuts and coverage losses dent hospital and provider volumes?
20%▼ 6–18 months
What if Vaccine-maker COVID-revenue cliff drags Moderna/Pfizer into losses?
17%▼ 6–18 months
What if Biotech-equity rout as funding dries and trials disappoint?